IA2030 Scorecard
—Global
Type to select a Country
SP 4: Life Course & Integration
4.1
Life-course vaccination
Breadth of protection (Mean Coverage across 12 antigens, %)—Global
Average (Mean) Coverage
71%
Baseline
69%
2021
72%
2022
74%
2023
3rd dose of diphtheria-tetanus-pertussis-containing vaccine (DTPcv3)
86%
Baseline
81%
2021
84%
2022
84%
2023
3rd dose of hepatitis B vaccine (HepB3)
86%
Baseline
81%
2021
84%
2022
83%
2023
3rd dose of Haemophilus influenzae type b vaccine (Hib3)
74%
Baseline
72%
2021
77%
2022
77%
2023
Final dose of human papillomavirus vaccine (HPV)
14%
Baseline
13%
2021
18%
2022
33%
2023
1st dose of inactivated poliovirus vaccine (IPV1)
84%
Baseline
82%
2021
85%
2022
84%
2023
1st dose of measles-containing vaccine (MCV1)
86%
Baseline
81%
2021
83%
2022
83%
2023
2nd dose of measles-containing vaccine (MCV2)
71%
Baseline
71%
2021
73%
2022
74%
2023
3rd dose of pneumococcal conjugate vaccine (PCV3)
51%
Baseline
52%
2021
61%
2022
65%
2023
3rd dose of polio vaccine (POL3)
86%
Baseline
81%
2021
84%
2022
83%
2023
1st dose of rubella-containing vaccine (RCV1)
69%
Baseline
66%
2021
72%
2022
71%
2023
Final dose of rotavirus vaccine series (ROTAC)
40%
Baseline
49%
2021
52%
2022
55%
2023
Summary Table
| Antigen | Baseline (2019) | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Average (Mean) Coverage | 71% | 69% | 72% | 74% |
| 3rd dose of diphtheria-tetanus-pertussis-containing vaccine (DTPcv3) | 86% | 81% | 84% | 84% |
| 3rd dose of hepatitis B vaccine (HepB3) | 86% | 81% | 84% | 83% |
| 3rd dose of Haemophilus influenzae type b vaccine (Hib3) | 74% | 72% | 77% | 77% |
| Final dose of human papillomavirus vaccine (HPV) | 14% | 13% | 18% | 33% |
| 1st dose of inactivated poliovirus vaccine (IPV1) | 84% | 82% | 85% | 84% |
| 1st dose of measles-containing vaccine (MCV1) | 86% | 81% | 83% | 83% |
| 2nd dose of measles-containing vaccine (MCV2) | 71% | 71% | 73% | 74% |
| 3rd dose of pneumococcal conjugate vaccine (PCV3) | 51% | 52% | 61% | 65% |
| 3rd dose of polio vaccine (POL3) | 86% | 81% | 84% | 83% |
| 1st dose of rubella-containing vaccine (RCV1) | 69% | 66% | 72% | 71% |
| Final dose of rotavirus vaccine series (ROTAC) | 40% | 49% | 52% | 55% |
The metadata for this indicator can be viewed here. The metadata typically includes the indicator's definitions, method of estimation, limitations, and sources.
Accessed: undefined
